Dr. Svensson on the Impact of PD-L1 Status in Gastric and Esophageal Adenocarcinoma

Maria Svensson, MD
Published: Tuesday, Mar 27, 2018



Maria Svensson, MD, Lund University, discusses the impact of determining PD-L1 status for patients with esophageal and gastric adenocarcinoma.

In a study of patients with resectable esophageal and gastric cancer, investigators sought to examine the expression of PD-L1 in tumor cells and tumor-infiltrating immune cells, and the PD-1 receptor as it relates to mismatch repair (MMR) status.

It is important to find good biomarkers for prognosis, explains Svensson. Patients with high PD-L1 expression in tumor-infiltrating lymphocytes (TILs) had prolonged survival. In this study, the prognostic value was evident in MMR-proficient tumors. PD-L1 expression and MMR status can be useful in the clinic in the future for different settings, adds Svensson.
 


Maria Svensson, MD, Lund University, discusses the impact of determining PD-L1 status for patients with esophageal and gastric adenocarcinoma.

In a study of patients with resectable esophageal and gastric cancer, investigators sought to examine the expression of PD-L1 in tumor cells and tumor-infiltrating immune cells, and the PD-1 receptor as it relates to mismatch repair (MMR) status.

It is important to find good biomarkers for prognosis, explains Svensson. Patients with high PD-L1 expression in tumor-infiltrating lymphocytes (TILs) had prolonged survival. In this study, the prognostic value was evident in MMR-proficient tumors. PD-L1 expression and MMR status can be useful in the clinic in the future for different settings, adds Svensson.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x